Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

(2019) Bastian Schilling et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

(2019) Sophia Kreft et al.   EUROPEAN JOURNAL OF CANCER

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint

(2018) Melissa D. Curtis et al.   HEALTH SERVICES RESEARCH

Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Sequencing Treatment in BRAFV600 Mutant Melanoma

(2017) Douglas B. Johnson et al.   JOURNAL OF IMMUNOTHERAPY

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models

(2017) Zhiqiang Guo et al.   Oncotarget

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience

(2016) Stefano Cavalieri et al.   TUMORI

Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience

(2016) Stefano Cavalieri et al.   TUMORI JOURNAL

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications